Physician profile
Michael Yu
NPI 1942240874
$5,249.38
in general payments reported to CMS, 2019-2025
37 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $259 · 2021: $184 · 2022: $916 · 2023: $1,172 · 2024: $1,123 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $699.80 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $605.59 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Novo Nordisk INC | $496.24 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $485.08 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $387.70 | 2019-2025 | Veozah |
| Lilly USA, LLC | $350.01 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $242.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $226.55 | 2019-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Pfizer INC. | $197.48 | 2019-2024 | |
| Erbe USA INC | $166.65 | 2024 | |
| Glaxosmithkline, LLC. | $165.93 | 2019-2025 | Shingrix, Arexvy |
| Radius Health, INC. | $132.28 | 2020-2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $113.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $106.52 | 2019-2022 | |
| Sanofi Pasteur INC. | $96.05 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.